TRIA
HRMY icon

Trail Ridge Investment Advisors’s Harmony Biosciences HRMY Stock Holding History

Trail Ridge Investment Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Buy
8,934
+240
+3% +$7.57K 0.14% 77
2026
Q1 		$244K Buy
8,694
+385
+5% +$12.6K 0.11% 94
2025
Q4 		$311K Sell
8,309
-535
-6% -$17.6K 0.13% 89
2025
Q3 		$244K Buy
8,844
+300
+4% +$10.3K 0.11% 99
2025
Q2 		$301K Sell
8,544
-1,266
-13% -$40.7K 0.14% 86
2025
Q1 		$326K Buy
9,810
+766
+8% +$27.5K 0.17% 82
2024
Q4 		$311K Sell
9,044
-8
-0.1% -$275 0.15% 89
2024
Q3 		$308K Sell
9,052
-220
-2% -$7.73K 0.15% 92
2024
Q2 		$280K Buy
9,272
+1,015
+12% +$30.5K 0.14% 93
2024
Q1 		$277K Buy
+8,257
New +$265K 0.16% 90

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Trail Ridge Investment Advisors's HRMY Position: Q2 2026 in Review

Trail Ridge Investment Advisors increased its Harmony Biosciences (HRMY) stake by 2.8% in Q2 2026, buying an estimated $7.57K and bringing the position to 8,934 shares worth $325K. The position accounts for 0.14% of the portfolio, ranked #77.

Trail Ridge Investment Advisors first reported a position in HRMY in Q1 2024 and has held it in 10 quarters since. The position peaked at $326K in Q1 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Trail Ridge Investment Advisors held 8,934 shares of Harmony Biosciences worth $325K as of Q2 2026.
  • Trail Ridge Investment Advisors bought 240 Harmony Biosciences shares in Q2 2026, an estimated $7.57K.
  • Harmony Biosciences made up 0.14% of Trail Ridge Investment Advisors's portfolio in Q2 2026, its #77 holding.
  • Trail Ridge Investment Advisors first reported a position in Harmony Biosciences in Q1 2024 and has held it in 10 quarters since.
  • Trail Ridge Investment Advisors's Harmony Biosciences position peaked at $326K in Q1 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Trail Ridge Investment Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.